Our observations of altered PTEN chromatin interactions support the mechanistic context of a recently described therapeutic strategy (Schade et al., 2024), as EZH2 inhibition may restore normal chromatin architecture around the PTEN locus, thereby reestablishing tumor suppressor function and enhancing sensitivity to AKT inhibition. The gene discussed is PTEN; the disease is neoplasm.